Summary
Background
An 81-year-old man with torrential functional tricuspid regurgitation (TR) had recurrent heart failure despite optimal medical therapy. Because of severe annular dilatation (diameter 72 mm, gap 18 mm) and a dilated inferior vena cava (65 mm), none of the commercially available transcatheter devices was suitable.
Methods
With approval from the national authorities for compassionate use, a Pivot Extend® spacer (Tau Medical) was implanted via the right femoral vein under general anaesthesia with transoesophageal echocardiographic guidance. The device body was inflated to 12 mm, and the spiral anchor was deployed in the inferior vena cava.
Results
TR was reduced by approximately 50% during the procedure, without notable complications. TR remained massive (vena contracta 30 mm at baseline, 16 mm at discharge and at follow-up on day 24). Right ventricular stroke volume index improved from 30 mL/m² at baseline to 45 mL/m² at discharge and 46 mL/m² at follow-up.
Conclusions
The device was fixed in the anterior–posterior axis but could move in the septal–lateral axis, so it positioned itself centrally in the valve. The authors state that further clinical data are required to assess the efficacy and safety of this technology.
No abstract is available for this article. This summary was prepared by Tau Medical from the full text; read the full article on the publisher's site.
Related publications
CCI 2026 · Clinical
Safety and Efficacy of Pivot-Bridge for Severe Functional Tricuspid Regurgitation: The First-in-Human Experiences
View detailsKCJ 2025 · Clinical
Safety and Efficacy of Pivot-Balloon for Severe Tricuspid Regurgitation: The First-in-Man Experiences
View detailsApplied Sciences 2024 · Engineering & simulation
